 phase II trial pentostatin refractori lymphoma cutan t-cell diseas thirty-seven patient refractori lymphoma cutan t-cell lymphoma pentostatin dcf intraven IV bolu consecut day cycl eastern cooper oncolog group ecog trial diagnosi non-hodgkin lymphoma hodgkin diseas cutan t-cell lymphoma ctcl unknown subtyp elig major convent chemotherapi regimen ten elig patient partial respons PR patient nodular lymphocyt npdl nodular mix NM lymphocyt dpdl histiocyt DH lymphoma mixed-cellular MC hodgkin diseas unknown subtyp patient ctcl overal median time treatment failur ttf month rang month overal respons durat month rang month overal median surviv month rang month major patient toxic instanc sever life-threaten event fatal toxic patient underli pulmonari condit prior cardiac histori studi dcf activ refractori lymphoma ctcl patient histori seriou pulmonari cardiac diseas warrant consider incorpor low-dosag schedul convent combin chemotherapi regimen use biolog respons modifi